中国药业2016，Vol.25Issue(19)：1-5,5.
阿尔茨海默病免疫治疗新进展及其药物研发展望
Advances in Immunotherapies and Drug Development Prospect for Alzheimer's Disease
于红梅 1方宇2
作者信息
- 1. 西安交通大学医学部药学院药事管理与临床药学系，陕西 西安 710061
- 2. 西安交通大学药品安全与政策研究中心，陕西 西安 710061
- 折叠
摘要
Abstract
The main pathological signature of Alzheimer disease ( AD ) is characterized by β amyloid deposits in the form of extracellular amyloid β ( Aβ) plaques and tau protein aggregates in the form of intracellular neurofibrillary tangles ( NFT ) . An exciting new approach to treat AD is the immunization approach. Immunotherapeutic agents mainly include nonsteroidal anti-inflammatory drugs ( NSAID ) , pas-sive and active immunization. Recent studies have indicated that AD clinical progress can't be slowed only by cleaning Aβ, and the current main development direction is the immunotherapy targeting tau protein. More and more researchers and pharmaceutical companies start paying attention to AD immunotherapy. Although facing great challenge, huge economic and social returns will be delivered by suc-ceeding in AD drug development.关键词
阿尔茨海默病/免疫治疗/药物研发Key words
Alzheimer's disease/immunotherapy/drug research & development分类
医药卫生引用本文复制引用
于红梅,方宇..阿尔茨海默病免疫治疗新进展及其药物研发展望[J].中国药业,2016,25(19):1-5,5.
